Servier in deal with CIMA in Alzheimer and Parkinson research
French independent drugmaker Servier has signed a collaboration agreement with the Center for Applied Medical Research (CIMA of the University of Navarra, Spain, to research two of the most prevalent neurodegenerative diseases in the world: Alzheimer’s and Parkinson’s diseases.
Through this alliance the pharmaceutical company supports CIMA in order to increase scientific knowledge on the treatment of these diseases and to carry out in-depth research into the causes and mechanisms which produce neurodegeneration. No financial details of the accord were disclosed.
The first agreement is to research the potential of a new target which has been identified in CIMA for the treatment of Alzheimer’s disease. Study of the target will allow for better understanding the disease, and the identification and development of potential new therapeutic agents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze